Shareholding for the Period Ended March 31, 2017
Lyka Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here19-04-2017
19-04-2017
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Narendra Ishwarlal Gandhi (HUF)17-04-2017
Statement Of Investor Complaints For The Quarter Ended 31St March, 2017
The Company has received one complaint in respect of its listed Securities i.e. shares during the quarter ended 31st March, 2017 which has since been resolved and there is no complaint at the end of the Quarter.11-04-2017
Certificate Under Regulation 40(9) Of SEBI (LODR), 2015
As per requirement of Regulation 40 (9) of SEBI (Listing Obligation & Disclosure Requirement) Regulations, 2015, we are sending herewith certificate dated 10th April, 2017 issued by P.P Shah & Co, Company Secretary in practice for the half year ended 31st March, 2017.11-04-2017
Compliance Certificate For The Period Ended 31St March, 2017
We submit herewith Compliance certificate for the half year ended 31st March, 2017 duly signed by our RTA i.e. Sharex Dynamic (India) Private Limited and Compliance officer of the Company pursuant to Regulation 7 (3) of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015.07-04-2017
Updates
We wish to inform you that as advised by our Consultant, the Board of Directors at their meeting held on Saturday, 01st April, 2017 have reconsidered the date of merger of Lyka Healthcare Ltd, wholly owned subsidiary with Lyka Labs Ltd w.e.f. 01st April, 2017 as against 01st April, 2016 reported earlier to the exchange.03-04-2017
Standalone & Consolidated Financial Results, Limited Review Report for December 31, 2016
Lyka Labs Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Consolidated Financial Results for the period ended December 31, 20163. Standalone Limited Review for the period ended December 31, 20164. Consolidated Limited Review for the period ended December 31, 201614-02-2017
Board Meeting Intimation for Results & Closure of Trading Window
Lyka Labs Ltd has informed BSE that the Board Meeting is convened on February 14, 2017, to consider and take on record Unaudited Standalone and Consolidated Financial Results for the Third Quarter ended December 31, 2016.Trading Window will remain closed for a period of 9 days i.e. February 07, 2017 to February 15, 2017 (both days inclusive).06-02-2017
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Enai Trading And Investment Pvt Ltd18-01-2017
Shareholding for the Period Ended December 31, 2016
Lyka Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here16-01-2017